The Daily Differential — Saturday, July 11, 2026

Anticoagulant Reversal

Intracranial, retroperitoneal, airway, and hemodynamically significant bleeding can deteriorate within minutes. Reversal is a race between ongoing hemorrhage, delayed antidote administration, and thrombosis from overcorrection.

By the Blue Fish Med Desk Jul 11, 2026 · Phoenix

0:00 / –:–– AI‑generated audio

A 72-year-old man arrives with a sudden, explosive headache and vomit on his shirt, his wife gripping a medication list that trembles in her hand. He is somnolent but opens his eyes to voice; his right arm drifts toward the stretcher rail. The CT scanner is ready, but the medication list shows a blood thinner and the laboratory result that will determine the antidote is still pending.

— What’s your move? Read on.

Before you read

When is empiric reversal justified before the assay returns?
What complication can reversal itself cause?

When to Think of It

Enter the pathway for life-threatening bleeding, critical-site bleeding, urgent surgery, or serious hemorrhage with shock in a patient taking warfarin, unfractionated heparin, LMWH, dabigatran, apixaban, rivaroxaban, edoxaban, or betrixaban. Ask for the last dose, indication, renal function, adherence, and co-medications; bring the medication bottles or pharmacy record if possible.

Sick or Not Sick

The pivotal call is major/critical-site bleeding versus nonmajor bleeding. Intracranial hemorrhage, airway bleeding, hemodynamic instability, expanding hematoma, or bleeding requiring transfusion/procedure warrants immediate reversal while testing proceeds.

The First Fifteen Minutes

All major bleeds: Two large-bore IVs, type and crossmatch, CBC, PT/INR, aPTT, fibrinogen, creatinine, anti-Xa or thrombin time when available, and immediate source-control imaging. Activate a massive transfusion pathway if shock is present.
Warfarin with major bleeding or INR ≥2: Give vitamin K 10 mg IV slowly plus 4-factor PCC 25–50 units/kg IV based on INR (maximum 2,500–5,000 units; follow product protocol), because PCC rapidly replaces factors while vitamin K sustains synthesis. Check the local PCC dosing table.
Dabigatran with major bleeding: Give idarucizumab 5 g IV as two consecutive 2.5-g doses, because it binds dabigatran immediately. If unavailable, use 4-factor PCC 50 units/kg IV with hematology/toxicology input; dialysis may help because dabigatran is dialyzable.
Apixaban, rivaroxaban, or edoxaban with life-threatening bleeding: If available, give andexanet alfa—low dose 400 mg IV bolus then 4 mg/min infusion for 120 minutes, or high dose 800 mg bolus then 8 mg/min for 120 minutes according to agent, dose, and timing. If unavailable, give 4-factor PCC 50 units/kg IV; confirm institutional protocol because practice and availability vary.
Unfractionated heparin: Stop heparin; if bleeding is major or urgent reversal is needed, give protamine 1 mg IV per 100 units of heparin received in the preceding 2–3 hours, maximum 50 mg, slowly, because it neutralizes heparin. Recalculate for the actual recent infusion.
Enoxaparin or another LMWH: If a major bleed occurred within 8 hours, give protamine 1 mg IV per 1 mg enoxaparin; if 8–12 hours ago, 0.5 mg per 1 mg. Reversal is incomplete; obtain expert guidance.
Shock: Give balanced crystalloid in small reassessed boluses and blood products early; avoid allowing resuscitation to delay antidote or source control.

Definitive Care & Disposition

Reverse the drug while pursuing source control: emergent neurosurgical consultation for ICH, endoscopy or interventional radiology for GI bleeding, operative control for compressible or expanding hemorrhage, and airway intervention when needed. Repeat hemoglobin, INR/aPTT, fibrinogen, neurologic examination, and imaging according to the bleeding site. All critical-site bleeds require ICU-level care; resume anticoagulation later only after bleeding control and a documented thrombotic-risk discussion.

How This One Kills

The lethal error is waiting for a “confirmatory” drug level or INR before reversing a deteriorating intracranial bleed—especially when the medication history already identifies the anticoagulant.

The Differential — What Else Looks Like This

Thrombotic stroke — focal deficit with vessel occlusion rather than hemorrhage; confusing the two can delay reperfusion or cause catastrophic bleeding.
Subdural empyema or meningitis — headache and altered mental status with infectious features; anticoagulant reversal alone delays antibiotics and drainage.
Spontaneous retroperitoneal bleed — flank pain, femoral neuropathy, falling hemoglobin, and shock with little external blood; missing it leads to delayed embolization or surgery.
Traumatic hemorrhage — apparently minor trauma may conceal expanding intracranial or abdominal bleeding; falsely reassuring examination delays imaging.

The Second-Day Story

Older adults may present with isolated confusion, weakness, a fall, anemia, or hypotension rather than obvious bleeding. A partially treated patient may have a near-normal INR despite clinically important factor-Xa inhibition, while renal failure can prolong dabigatran effect long after the reported last dose. Treat the clinical bleeding syndrome and medication exposure—not a single reassuring laboratory value.

Back to Our Patient

Back to the 72-year-old man with the explosive headache and right-arm drift: he has a critical-site bleed until proven otherwise, so he is recognized as sick and receives airway-ready resuscitation, urgent CT, type and crossmatch, and immediate medication reconciliation. CT demonstrates intracerebral hemorrhage, and his list confirms warfarin; reversal begins before waiting for every laboratory result with IV vitamin K 10 mg plus INR-guided 4-factor PCC. Neurosurgery and neurocritical care take over, repeat imaging confirms stability, and he is admitted to the neuro-ICU.

Patient Presentation to Attending

How you’d present this patient on the floor — tight, pertinent positives and negatives, no rambling

“This is a 72-year-old man with sudden severe headache, vomiting, somnolence, and new right-arm drift while taking warfarin for atrial fibrillation. Symptoms began 45 minutes ago, with no reported trauma or seizure, and his wife confirms no missed doses or recent medication changes. He is protecting his airway but is drowsy, hypertensive, and has right-sided weakness; there is no external bleeding. CT shows an acute intracerebral hemorrhage, and we are sending CBC, INR, fibrinogen, type and crossmatch, and renal function. This is life-threatening warfarin-associated intracranial bleeding, so I recommend immediate IV vitamin K and 4-factor PCC, neurocritical-care admission, and emergent neurosurgical consultation.”

Study Directive

Draw a one-page reversal algorithm from memory for warfarin, UFH, LMWH, dabigatran, and factor-Xa inhibitors.
Practice three medication-history cases and select reversal without waiting for a drug level.
Review your institutional PCC and andexanet protocols; verify all doses in Lexicomp, UpToDate, or the local antidote guideline.
Rehearse a 30-second critical-bleed activation call including anticoagulant, last dose, bleed site, and reversal request.

Recent Literature

Review or guideline Blood-Product Transfusion and Antithrombotic-Agent Reversal
Morrisroe KA, Stanley EK, Borloz MP · Emerg Med Clin North Am, 2025 · PMID 40610056

Provides an up-to-date emergency department framework for selecting blood products and specific or nonspecific reversal agents in patients with life-threatening bleeding on antithrombotic therapy.

4 of 4

von Willebrand Disease

vWD is the most common inherited bleeding disorder and often presents to the ED as epistaxis, dental bleeding, menorrhagia, or postpartum hemorrhage....

0:00 / –:–– AI‑generated audio

The Case

A 20-year-old college student holds a blood-soaked towel beneath her nose while a roommate describes two hours of bleeding and a history of “very heavy periods.” She is pale but talking comfortably, and the towel is filling more slowly. Her platelet count and INR are normal; the unresolved question is how to stop this bleeding without assuming that a normal screening panel means normal hemostasis.

Before You Read

What bleeding pattern points toward a primary-hemostasis disorder?
When should desmopressin be used, and when can it fail or harm?
Which patients need factor replacement and admission?

Why It Matters

vWD is the most common inherited bleeding disorder and often presents to the ED as epistaxis, dental bleeding, menorrhagia, or postpartum hemorrhage. Standard PT and platelet count may be normal, so recognition depends heavily on the bleeding history.

When to Think of It

Think of vWD with lifelong mucocutaneous bleeding, prolonged or recurrent epistaxis, easy bruising, heavy menstrual bleeding, excessive bleeding after dental work or surgery, postpartum hemorrhage, or a family history. Acquired vWD is possible with lymphoproliferative disease, mechanical circulatory devices, autoimmune disease, or extreme thrombocytosis.

Sick or Not Sick

The decisive call is controlled mucosal bleeding versus ongoing major bleeding, hemodynamic compromise, airway risk, or bleeding in a critical site. Check the severity, hemoglobin, pregnancy/postpartum status, bleeding site, vWD type if known, and prior response to desmopressin.

The First Fifteen Minutes

Apply firm uninterrupted local pressure; establish IV access for ongoing heavy bleeding and obtain CBC, type and screen, PT/aPTT, fibrinogen, pregnancy test when relevant, and vWF antigen/activity and factor VIII if available. Do not delay treatment for send-out testing.
Active mucosal bleeding or dental/gynecologic bleeding in a patient known or likely to respond to DDAVP: give desmopressin 0.3 mcg/kg IV over 15–30 minutes, maximum 20 mcg, because it releases endothelial vWF and factor VIII. Restrict free water and monitor sodium because hyponatremia and seizures can occur; avoid or obtain specialist advice in type 2B vWD, significant cardiovascular disease, or prior nonresponse.
Mucosal bleeding: give tranexamic acid 1 g IV over 10 minutes (or 1.3 g PO three times daily when oral therapy is appropriate), because antifibrinolysis stabilizes clot at mucosal surfaces. Avoid in active intravascular thrombosis and use renal adjustment.
Major bleeding, severe vWD, DDAVP nonresponse/contraindication, or urgent surgery: give a vWF-containing concentrate, commonly 40–60 IU/kg IV as an initial dose for major bleeding, then repeat based on product, levels, and clinical response. Dosing varies substantially—check the specific product and hematology protocol.
Life-threatening anemia or hemorrhage: transfuse packed RBCs based on hemodynamics and symptoms, while pursuing source control; do not rely on DDAVP alone.

Definitive Care & Disposition

Use ENT, gynecology, dental, gastroenterology, or surgery for source control. Hematology should guide vWF concentrate, factor VIII monitoring, and perioperative targets. Admit ongoing heavy bleeding, symptomatic anemia, pregnancy/postpartum hemorrhage, airway risk, critical-site bleeding, or need for repeated factor therapy; stable patients with controlled bleeding require hematology follow-up and a written medication/procedure plan.

How This One Kills

The classic failure is assuming normal PT and platelet count exclude a bleeding disorder, then discharging a patient with ongoing mucosal bleeding who needs vWF-directed therapy.

The Atypical Presentation

Some patients are diagnosed only after dental extraction, childbirth, or surgery because spontaneous bleeding is mild. A normal aPTT does not exclude vWD, and factor VIII may normalize during stress, pregnancy, or inflammation, obscuring the diagnosis. Recurrent mucosal bleeding plus a family history should prompt repeat specialized testing when the patient is well.

Back to Our Patient

Back to the 20-year-old with the blood-soaked towel and heavy menstrual history: she has a primary-hemostasis pattern with normal platelets and INR, making vWD a leading diagnosis. She remains stable after sustained pressure, but ongoing epistaxis warrants IV access, CBC and type-and-screen, hematology/ENT input, tranexamic acid, and—after confirming no contraindication—desmopressin 0.3 mcg/kg IV with fluid restriction. The bleeding stops, hemoglobin is acceptable, specialized vWF testing is sent, and she is observed before discharge with hematology follow-up and explicit return precautions.

Patient Presentation to Attending

“This is a 20-year-old woman with two hours of epistaxis and a lifelong history of heavy menstrual bleeding and easy bruising. She is pale but hemodynamically stable, has no airway compromise or other active bleeding, and her platelet count and INR are normal. The pattern suggests an inherited primary-hemostasis disorder, most likely von Willebrand disease, rather than thrombocytopenia or hemophilia. I recommend continued direct pressure, CBC and type-and-screen, vWF studies, tranexamic acid, and desmopressin if hematology agrees and there is no contraindication. If bleeding recurs or hemoglobin is low, she will need vWF concentrate and admission.”

Study Directive

Construct a bleeding-history checklist distinguishing mucocutaneous bleeding from deep tissue/joint bleeding.
Memorize DDAVP dose, infusion duration, fluid restriction, and the major contraindication warnings.
Review local vWF concentrate products and calculate one adult dose using the product-specific protocol.
Practice three cases with normal PT/aPTT but clinically significant bleeding and decide when to send specialized vWF testing.

---

Mechanism Pearl of the Day: Platelets sit at the intersection of all four topics: too few impair primary hemostasis, too many can cause both thrombosis and acquired vWF loss, dysfunctional platelets produce mucosal bleeding despite a normal count, and anticoagulants amplify the consequences of any defect in clot formation.

Key Medications

Desmopressin: 0.3 mcg/kg IV over 15–30 minutes, maximum 20 mcg; fluid restriction and sodium monitoring are important.
Tranexamic acid: 1 g IV over 10 minutes or 1.3 g PO three times daily; renal dosing and thrombosis contraindications require reference checking.
vWF-containing concentrate: commonly 40–60 IU/kg IV initially for major bleeding, but dosing differs by product and target—check Lexicomp, UpToDate, the package insert, or institutional hematology protocol.
Packed RBCs: transfuse according to hemorrhage severity, symptoms, and comorbid disease.
Pediatric and pregnancy dosing should be managed with hematology/obstetric guidance.

High-Yield Pearls

Normal PT and platelet count do not rule out vWD; the bleeding history is often more sensitive than screening tests.
DDAVP is a trial-dependent therapy: response varies by subtype, and repeated doses may produce tachyphylaxis.
Heavy menstrual bleeding may be the only lifelong clue; ask specifically about dental, surgical, postpartum, and family bleeding.

The Mimics

Platelet dysfunction from aspirin/uremia — medication or renal history and abnormal platelet function; confusing it with vWD misses dialysis or drug withdrawal.
Hemophilia A — deep muscle/joint bleeding and isolated prolonged aPTT; treating with DDAVP alone may be inadequate.
Immune thrombocytopenia — petechiae with a low platelet count; confusing it with vWD leads to unnecessary factor treatment and misses thrombocytopenia.
Menorrhagia from structural gynecologic disease — abnormal pelvic findings or imaging; attributing all bleeding to vWD delays source control.

Board Question

A patient with known type 1 von Willebrand disease presents with mild-to-moderate epistaxis. She previously had an excellent response to desmopressin. Which treatment is most appropriate?

ADesmopressin 0.3 mcg/kg IV
BVitamin K 10 mg IV
CPlatelet transfusion regardless of platelet count
DProtamine 1 mg per 100 units of heparin

Reveal answer

Correct: A

Desmopressin releases stored vWF and factor VIII and is appropriate in responsive type 1 disease. Fluid restriction and sodium monitoring are required because of hyponatremia risk.

Recent Literature

Review or guideline Diagnosis and treatment of von Willebrand disease in 2024 and beyond
Haemophilia, 2024 · cited 26×

Provides a current, practical framework for confirming suspected von Willebrand disease and selecting bleeding-directed therapy, including desmopressin, von Willebrand factor replacement, and antifibrinolytics.

Full text · open access

TheDaily Differential

Anticoagulant Reversal

When to Think of It

Sick or Not Sick

The First Fifteen Minutes

Definitive Care & Disposition

How This One Kills

The Second-Day Story

Study Directive

Recent Literature

More in Today's Issue

Approach to Thrombocytopenia

Thrombocytosis

von Willebrand Disease

Yesterday’s Differential

Journal Watch

EM@3AM: Cortical Hand-Knob Stroke Mimicking Peripheral Nerve Injury

Podcast Picks

High-Flow or Standard O2 for Hypoxemic Respiratory Failure?

Ep 220 Facial Injuries: Assessment, Management and Disposition

Critical Care Corner

Heparin

Pharmacology Corner

Metronidazole

Flumazenil

ECG of the Day

Case of the Day